Compare SOHU & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOHU | AGEN |
|---|---|---|
| Founded | 1996 | 1994 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.1M | 274.8M |
| IPO Year | 2018 | 1999 |
| Metric | SOHU | AGEN |
|---|---|---|
| Price | $13.62 | $6.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $20.00 | $14.50 |
| AVG Volume (30 Days) | 58.0K | ★ 996.7K |
| Earning Date | 05-18-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.96 |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | $1.61 | $107.63 |
| Revenue Next Year | $3.78 | N/A |
| P/E Ratio | ★ $1.16 | $7.15 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $11.61 | $2.71 |
| 52 Week High | $17.30 | $8.85 |
| Indicator | SOHU | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 44.89 |
| Support Level | $13.38 | $2.97 |
| Resistance Level | $13.61 | $8.70 |
| Average True Range (ATR) | 0.50 | 0.53 |
| MACD | -0.12 | -0.21 |
| Stochastic Oscillator | 19.34 | 12.37 |
Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.